JP2013542914A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013542914A5 JP2013542914A5 JP2013519791A JP2013519791A JP2013542914A5 JP 2013542914 A5 JP2013542914 A5 JP 2013542914A5 JP 2013519791 A JP2013519791 A JP 2013519791A JP 2013519791 A JP2013519791 A JP 2013519791A JP 2013542914 A5 JP2013542914 A5 JP 2013542914A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- seq
- binding fragment
- amyloid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 19
- 102000036639 antigens Human genes 0.000 claims 19
- 108091007433 antigens Proteins 0.000 claims 19
- 239000012634 fragment Substances 0.000 claims 19
- 239000003446 ligand Substances 0.000 claims 15
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 12
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 12
- 239000003814 drug Substances 0.000 claims 7
- 238000000034 method Methods 0.000 claims 6
- 210000002569 neuron Anatomy 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 102000013498 tau Proteins Human genes 0.000 claims 3
- 108010026424 tau Proteins Proteins 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 claims 1
- 230000002238 attenuated effect Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000003647 oxidation Effects 0.000 claims 1
- 238000007254 oxidation reaction Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000026731 phosphorylation Effects 0.000 claims 1
- 238000006366 phosphorylation reaction Methods 0.000 claims 1
- 230000009822 protein phosphorylation Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36421010P | 2010-07-14 | 2010-07-14 | |
| US61/364,210 | 2010-07-14 | ||
| PCT/US2011/043866 WO2012009442A2 (en) | 2010-07-14 | 2011-07-13 | Anti-addl monoclonal antibody and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013542914A JP2013542914A (ja) | 2013-11-28 |
| JP2013542914A5 true JP2013542914A5 (OSRAM) | 2014-08-28 |
| JP5934203B2 JP5934203B2 (ja) | 2016-06-15 |
Family
ID=45470057
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013519791A Active JP5934203B2 (ja) | 2010-07-14 | 2011-07-13 | 抗ａｄｄｌモノクローナル抗体およびこの使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20130115227A1 (OSRAM) |
| EP (1) | EP2593475B1 (OSRAM) |
| JP (1) | JP5934203B2 (OSRAM) |
| KR (1) | KR101842301B1 (OSRAM) |
| CN (1) | CN103140500B (OSRAM) |
| AU (1) | AU2011279221B2 (OSRAM) |
| BR (1) | BR112013000796B1 (OSRAM) |
| CA (1) | CA2805414C (OSRAM) |
| DK (1) | DK2593475T3 (OSRAM) |
| ES (1) | ES2573135T3 (OSRAM) |
| MX (1) | MX338640B (OSRAM) |
| RU (1) | RU2567808C2 (OSRAM) |
| WO (1) | WO2012009442A2 (OSRAM) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9176151B2 (en) | 2010-07-14 | 2015-11-03 | Acumen Pharmaceuticals, Inc. | Antibodies, kit and method for detecting amyloid beta oligomers |
| US9320793B2 (en) * | 2010-07-14 | 2016-04-26 | Acumen Pharmaceuticals, Inc. | Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42 |
| AU2012282825B2 (en) * | 2011-07-13 | 2016-05-26 | Merck Sharp & Dohme Corp. | Method for detection of amyloid beta oligomers in a fluid sample and uses thereof |
| UY34887A (es) * | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| ES2776706T3 (es) * | 2013-07-05 | 2020-07-31 | Genmab As | Anticuerpos contra CD3 humanizados o quiméricos |
| EP3508502B1 (en) | 2013-09-20 | 2023-04-26 | Bristol-Myers Squibb Company | Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors |
| EP3423080B1 (en) * | 2016-03-01 | 2024-01-24 | Macquarie University | Phosphorylated tau and p38gamma for treating a neurological condition |
| MX2019012076A (es) | 2017-05-30 | 2019-12-09 | Bristol Myers Squibb Co | Composiciones que comprenden un anticuerpo anti gen-3 de activacion del linfocito (lag-3) o un anticuerpo anti-lag-3 y un anticuerpo anti muerte celular programada 1 (pd-1) o anti ligando 1 de muerte celular programada (pd-l1). |
| AU2018277824A1 (en) | 2017-05-30 | 2019-10-17 | Bristol-Myers Squibb Company | Treatment of LAG-3 positive tumors |
| US12227567B2 (en) | 2017-07-25 | 2025-02-18 | Truebinding, Inc. | Treating cancer by blocking the interaction of TIM-3 and its ligand |
| CN116063520A (zh) | 2019-01-30 | 2023-05-05 | 真和制药有限公司 | 抗gal3抗体及其用途 |
| JP7685985B2 (ja) * | 2019-07-16 | 2025-05-30 | サノフイ | アルツハイマー病の処置のための中和抗アミロイドベータ抗体 |
| WO2021055670A1 (en) | 2019-09-20 | 2021-03-25 | Avx Corporation | Somatic cell-based electrical biosensor |
| CN116157151A (zh) | 2020-05-26 | 2023-05-23 | 真和制药有限公司 | 通过阻断半乳凝素-3治疗炎性疾病的方法 |
| TW202300517A (zh) | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | 抗類澱粉β抗體及其用途 |
| WO2022251048A1 (en) | 2021-05-24 | 2022-12-01 | Eli Lilly And Company | Anti-amyloid beta antibodies and uses thereof |
| CN116375857A (zh) * | 2023-03-30 | 2023-07-04 | 天津鸿宇泰生物科技有限公司 | 一种用于检测Tau蛋白的单链抗体及其制备方法和应用 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4493825A (en) | 1982-10-05 | 1985-01-15 | Iowa State University Research Foundation | Purified and antigenically selective vaccines for domestic animals |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| HU212924B (en) | 1989-05-25 | 1996-12-30 | Chiron Corp | Adjuvant formulation comprising a submicron oil droplet emulsion |
| ATE139258T1 (de) | 1990-01-12 | 1996-06-15 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US6797492B2 (en) | 1991-05-17 | 2004-09-28 | Merck & Co., Inc. | Method for reducing the immunogenicity of antibody variable domains |
| EP0746609A4 (en) | 1991-12-17 | 1997-12-17 | Genpharm Int | NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES |
| GB9225453D0 (en) | 1992-12-04 | 1993-01-27 | Medical Res Council | Binding proteins |
| US6218506B1 (en) | 1997-02-05 | 2001-04-17 | Northwestern University | Amyloid β protein (globular assembly and uses thereof) |
| ATE441432T1 (de) | 1997-03-10 | 2009-09-15 | Ottawa Hospital Res Inst | Verwendung von nicht-methyliertem cpg dinukleotid in kombination mit aluminium als adjuvantien |
| RU2353389C2 (ru) * | 2002-10-09 | 2009-04-27 | Ринат Ньюросайенс Корп. | Способы лечения болезни альцгеймера с использованием антител, направленных против пептида амилоида-бета, и их композиций |
| ES2246178B1 (es) * | 2003-05-08 | 2007-03-01 | Universidad De Zaragoza. | Uso de anticuerpos para el tratamiento de enfermedades amiloideas. |
| AU2005269940A1 (en) | 2004-07-02 | 2006-02-09 | Northwestern University | Monolocal antibodies that target pathological assemblies of amyloid beta (Abeta) |
| SG190665A1 (en) * | 2004-07-30 | 2013-06-28 | Rinat Neuroscience Corp | Antibodies directed against amyloid-beta peptide and methods using same |
| NZ554725A (en) * | 2004-10-25 | 2009-10-30 | Merck & Co Inc | Anti-ADDL antibodies and uses thereof |
| CA2790433A1 (en) * | 2004-10-25 | 2006-05-26 | Northwestern University | Anti-addl antibodies and uses thereof |
| US7700099B2 (en) | 2005-02-14 | 2010-04-20 | Merck & Co., Inc. | Non-immunostimulatory antibody and compositions containing the same |
| US7731962B2 (en) | 2005-02-14 | 2010-06-08 | Merck & Co., Inc. | Anti-ADDL monoclonal antibody and use thereof |
| ES2318918B1 (es) | 2005-04-01 | 2010-02-16 | Biotherapix Molecular Medicines, S.L.U. | Anticuerpos humanos con capacidad de union al peptido beta-amiloide y sus aplicaciones. |
| TW200726482A (en) | 2005-06-30 | 2007-07-16 | Merck & Co Inc | Method for preparing a covalently cross linked oligomer of amyloid beta peptides |
| TW200726774A (en) | 2005-06-30 | 2007-07-16 | Merck & Co Inc | Composition and method for producing stable amyloid beta oligomers |
| RU2008120027A (ru) * | 2005-10-21 | 2009-11-27 | Мерк энд Ко., Инк. (US) | Анти-addl моноклональное антитело и его применение |
-
2011
- 2011-07-13 JP JP2013519791A patent/JP5934203B2/ja active Active
- 2011-07-13 WO PCT/US2011/043866 patent/WO2012009442A2/en not_active Ceased
- 2011-07-13 ES ES11807457.4T patent/ES2573135T3/es active Active
- 2011-07-13 RU RU2013106270/10A patent/RU2567808C2/ru active
- 2011-07-13 AU AU2011279221A patent/AU2011279221B2/en active Active
- 2011-07-13 EP EP11807457.4A patent/EP2593475B1/en active Active
- 2011-07-13 KR KR1020137003618A patent/KR101842301B1/ko active Active
- 2011-07-13 BR BR112013000796-6A patent/BR112013000796B1/pt active IP Right Grant
- 2011-07-13 CN CN201180034706.4A patent/CN103140500B/zh active Active
- 2011-07-13 DK DK11807457.4T patent/DK2593475T3/en active
- 2011-07-13 US US13/809,475 patent/US20130115227A1/en not_active Abandoned
- 2011-07-13 MX MX2013000490A patent/MX338640B/es active IP Right Grant
- 2011-07-13 CA CA2805414A patent/CA2805414C/en active Active
-
2014
- 2014-07-09 US US14/326,974 patent/US9309309B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013542914A5 (OSRAM) | ||
| RU2013106270A (ru) | Моноклональное антитело против addl и его применения | |
| JP7019198B2 (ja) | 補体関連疾患の予防及び治療のためのｃ５抗体及び方法 | |
| AU2019257379B2 (en) | Use of semaphorin-4D binding molecules for treating neurodegenerative disorders | |
| JP6944375B2 (ja) | 発作性夜間血色素尿症（ｐｎｈ）患者の亜集団の同定および処置 | |
| TWI551609B (zh) | 抗－顆粒溶解素抗體及其應用 | |
| JP2023120208A (ja) | 補体成分ｃ５または血清アルブミンと結合するポリペプチドおよびその融合タンパク質 | |
| JP2019108359A (ja) | アテローム性動脈硬化の処置のためのセマフォリン−４ｄ結合分子の使用 | |
| AU2016353552B2 (en) | N-terminal epitopes in Amyloid beta and conformationally-selective antibodies thereto | |
| JP7186266B2 (ja) | 細胞内抗原に対して向けられた単一ドメイン抗体 | |
| AU2021258000A1 (en) | Antibody Molecules and Uses Thereof | |
| JP2020504759A (ja) | Ｓ．ａｕｒｅｕｓ溶血素ａ毒素に対するヒト抗体 | |
| CN112805299B (zh) | 针对原发性免疫缺陷、胱氨酸病和威尔逊病的新生儿筛查 | |
| EP3374381A1 (en) | Epitopes in amyloid beta mid-region and conformationally-selective antibodies thereto | |
| WO2025242094A1 (zh) | 靶向bdca2的抗体或其抗原结合片段及其应用 | |
| US12286469B2 (en) | Humanized antibodies binding to amyloid-beta (A-beta) | |
| CA2856866C (en) | Administration of alpha4beta7 hetero-dimer-specific antibody | |
| JP2020524988A (ja) | 抗ｒｏｂｏ２抗体、組成物、方法、およびその使用 | |
| CA3239286A1 (en) | Anti-c3 antibodies and antigen-binding fragments thereof and their uses for treating eye or ocular diseases | |
| EP3574020B1 (en) | Antibodies to amyloid beta | |
| CN108484765B (zh) | 一种抗人α-防御素-1单克隆抗体及其应用 | |
| WO2022081971A1 (en) | Notch4 antibodies and uses thereof | |
| EP2935324B1 (en) | Anti-staphylococcal antibodies | |
| US20250289877A1 (en) | Antibodies to Amyloid Beta | |
| JP7643727B2 (ja) | 抗－ｆｇｆ１９抗体 |